Next 10 |
AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately. The new name was chosen to better reflect the Company’s strategic focus on ...
Privately held Purdue Pharma LP has agreed to pay the state of Oklahoma $270M to settle litigation from the AG's office over its role in the opioid crisis there. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, Stocks on...
Proteostasis Therapeutics (NASDAQ: PTI ) -56% on disappointing data on CF candidates. More news on: Proteostasis Therapeutics, Inc., Recro Pharma, Inc., Motif Bio plc, Stocks on the move, Read more ...
Pain Therapeutics (NASDAQ: PTIE ): Q4 GAAP EPS of -$0.04. More news on: Pain Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
AUSTIN, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today reported financial results for the year ended December 31, 2018. Net loss in 2018 was $6.6 million, or $0.61 per share, compared to a net loss in 2017 of $11.9 million, or $1.82 per share. Cash us...
Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, ...
The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a report that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for...
Thinly traded nano cap Pain Therapeutics (NASDAQ: PTIE ) slumps 23% premarket on increased volume in reaction to the results from its meeting with the FDA aimed at getting its REMOXY ER (oxycodone extended-release CII) marketing application back on track. The company received a...
Pain Therapeutics (NASDAQ: PTIE ) -23% after announcing feedback from recent meeting with FDA on REMOXY. More news on: Pain Therapeutics, OPKO Health, Inc., Control4 Corporation, Global news and forex Read more ...
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S. Food and Drug Administration (FDA) regarding the drug candidate, REMOXY ER. R...
News, Short Squeeze, Breakout and More Instantly...
Pain Therapeutics Inc. Company Name:
PTIE Stock Symbol:
NASDAQ Market:
Pain Therapeutics Inc. Website:
AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately. The new name was chosen to better reflect the Company’s strategic focus on ...
AUSTIN, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today reported financial results for the year ended December 31, 2018. Net loss in 2018 was $6.6 million, or $0.61 per share, compared to a net loss in 2017 of $11.9 million, or $1.82 per share. Cash us...
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S. Food and Drug Administration (FDA) regarding the drug candidate, REMOXY ER. R...